OraSure Technologies (OSUR) : Domini Social Investments reduced its stake in OraSure Technologies by 10.52% during the most recent quarter end. The investment management company now holds a total of 76,061 shares of OraSure Technologies which is valued at $508,087 after selling 8,941 shares in OraSure Technologies , the firm said in a disclosure report filed with the SEC on May 12, 2016.OraSure Technologies makes up approximately 13.85% of Domini Social Investments’s portfolio.
Other Hedge Funds, Including , Group One Trading reduced its stake in OSUR by selling 15,547 shares or 92.54% in the most recent quarter. The Hedge Fund company now holds 1,254 shares of OSUR which is valued at $8,377.Manufacturers Life Insurance Company The reduced its stake in OSUR by selling 2,335 shares or 5.74% in the most recent quarter. The Hedge Fund company now holds 38,373 shares of OSUR which is valued at $256,332. Diam Ltd. added OSUR to its portfolio by purchasing 22,410 company shares during the most recent quarter which is valued at $148,802. Lebenthal Lisanti Capital Growth added OSUR to its portfolio by purchasing 92,085 company shares during the most recent quarter which is valued at $611,444. OraSure Technologies makes up approx 0.75% of Lebenthal Lisanti Capital Growth’s portfolio.
OraSure Technologies opened for trading at $6.71 and hit $7.03 on the upside on Friday, eventually ending the session at $6.84, with a gain of 1.79% or 0.12 points. The heightened volatility saw the trading volume jump to 5,28,641 shares. Company has a market cap of $379,504 M.
On the company’s financial health, OraSure Technologies reported $0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.02. The company had revenue of $29.10 million for the quarter, compared to analysts expectations of $28.82 million. The company’s revenue was up 7.4% compared to the same quarter last year.
OraSure Technologies Inc. (OraSure) is involved in the development manufacture marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test OraQuick ADVANCE OraSure HIV-1 oral specimen collection device OraQuick HCV rapid antibody test Intercept oral fluid drug testing system OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary DNA Genotek Inc. the Company provides oral fluid sample collection stabilization and preparation products for molecular diagnostic applications.